Biogen rises as investors react to fresh kidney-disease data and pipeline optimism

Biogen (BIIB) is up 4.6% today. Here is some analysis on what might have caused this price movement. ([investors.biogen.com](https://investors.biogen.com/news-releases/news-release-details/biogen-present-new-data-across-nephrology-portfolio-including))

Analysis: The most likely driver is renewed enthusiasm around Biogen’s nephrology franchise after the company outlined new long-term EMPAVELI data and additional kidney-disease presentations for this week’s major nephrology meeting. The move may also reflect continuing optimism that Biogen’s Apellis deal and broader late-stage pipeline can strengthen growth beginning in 2027, with earnings due on October 28, 2026. ([investors.biogen.com](https://investors.biogen.com/news-releases/news-release-details/biogen-present-new-data-across-nephrology-portfolio-including))

Details:

Sources:

Biogen, SEC, Investing.com

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$BIIB Insider Trading Activity

$BIIB insiders have traded $BIIB stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.

Here’s a breakdown of recent trading of $BIIB stock by insiders over the last 6 months:

• LLOYD MINOR has made 0 purchases and 2 sales selling 1,186 shares for an estimated $239,749.

To track insider transactions, check out Investivoq's insider trading dashboard. You can access data on insider stock transactions through the Investivoq API insider transaction endpoint.

$BIIB Hedge Fund Activity

We have seen 520 institutional investors add shares of $BIIB stock to their portfolio, and 380 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

• FMR LLC added 5,409,698 shares (+42.2%) to their portfolio in Q2 2026, for an estimated $1,168,819,349
• JPMORGAN CHASE & CO added 1,823,140 shares (+inf%) to their portfolio in Q2 2026, for an estimated $393,907,628
• PACER ADVISORS, INC. added 1,122,981 shares (+inf%) to their portfolio in Q2 2026, for an estimated $242,631,274
• SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 1,117,663 shares (+inf%) to their portfolio in Q2 2026, for an estimated $241,482,267
• VAN ECK ASSOCIATES CORP removed 981,752 shares (-90.9%) from their portfolio in Q2 2026, for an estimated $212,117,337
• POINT72 ASSET MANAGEMENT, L.P. removed 721,468 shares (-89.1%) from their portfolio in Q2 2026, for an estimated $155,880,376
• T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 664,588 shares (-85.4%) from their portfolio in Q2 2026, for an estimated $143,590,883

To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.

$BIIB Congressional Stock Trading

Members of Congress have traded $BIIB stock 7 times in the past 6 months. Of those trades, 4 have been purchases and 3 have been sales.

Here’s a breakdown of recent trading of $BIIB stock by members of Congress over the last 6 months:

• REPRESENTATIVE MARIA ELVIRA SALAZAR has traded it 5 times. They made 3 purchases worth up to $130,000 on 05/12, 05/11 and 2 sales worth up to $65,000 on 09/24, 06/02.
• REPRESENTATIVE KEVIN HERN sold up to $15,000 on 08/18.
• REPRESENTATIVE GILBERT RAY CISNEROS, JR. purchased up to $15,000 on 06/05.

To track congressional stock trading, check out Investivoq's congressional trading dashboard. You can access data on congressional stock trades through the Investivoq API Congress trades endpoint.

$BIIB Analyst Ratings

Wall Street analysts have issued reports on $BIIB in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

• Needham issued a "Buy" rating on 06/29/2026
• Evercore ISI Group issued a "Outperform" rating on 05/15/2026
• Guggenheim issued a "Buy" rating on 04/30/2026

To track analyst ratings and price targets for $BIIB, check out Investivoq's $BIIB forecast page.

$BIIB Price Targets

Multiple analysts have issued price targets for $BIIB recently. We have seen 8 analysts offer price targets for $BIIB in the last 6 months, with a median target of $223.5.

Here are some recent targets:

• Matthew Harrison from Morgan Stanley set a target price of $222.0 on 07/08/2026
• Brian Abrahams from RBC Capital set a target price of $242.0 on 07/07/2026
• Ami Fadia from Needham set a target price of $256.0 on 06/29/2026
• Salim Syed from Mizuho set a target price of $221.0 on 06/15/2026
• David Amsellem from Piper Sandler set a target price of $225.0 on 05/15/2026
• Geoff Meacham from Citigroup set a target price of $200.0 on 05/01/2026
• Laura Chico from Wedbush set a target price of $196.0 on 04/30/2026

This article is not financial advice. See Investivoq's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.